Chembio Diagnostics Inc Revenue Growth Rates (CEMI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Chembio Diagnostics Inc   (NASDAQ: CEMI)
 

CEMI's Revenue Growth by Quarter and Year

Chembio Diagnostics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CEMI Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 10.34
3rd Quarter September 11.20
2nd Quarter June 9.16
1st Quarter March 18.82
FY 49.52

CEMIs Annual Revenue
Chembio Diagnostics Inc 's Revenue in the fiscal year 2022 $ 49.52 millions
Chembio Diagnostics Inc 's Revenue in the fiscal year 2021 $ 47.82 millions
Chembio Diagnostics Inc 's Revenue in the fiscal year 2020 $ 32.47 millions
Chembio Diagnostics Inc 's Revenue in the fiscal year 2019 $ 34.46 millions
Chembio Diagnostics Inc 's Revenue in the fiscal year 2018 $ 33.41 millions




CEMI Revenue fourth quarter 2022 Y/Y Growth Comment
Chembio Diagnostics Inc reported drop in Revenue in the fourth quarter 2022 by -49.71% to $ 10.34 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Chembio Diagnostics Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 14.13%.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 251 other companies have achieved higher Revenue growth. While Chembio Diagnostics Inc ' s Revenue meltdown of -49.71% ranks overall at the positon no. 4457 in the fourth quarter 2022.


CEMI Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December -49.71 % 101.08 % 49.34 % -9.75 %
3rd Quarter September -7.13 % 17.43 % 5.66 % 3.62 %
2nd Quarter June 41.8 % 26.42 % -46.72 % 9.98 %
1st Quarter March 115.83 % 27.11 % -17.35 % 7.51 %
FY   3.58 % 47.24 % -5.77 % -

Financial Statements
Chembio Diagnostics Inc 's fourth quarter 2022 Revenue $ 10.34 millions CEMI's Income Statement
Chembio Diagnostics Inc 's fourth quarter 2021 Revenue $ 20.57 millions Quarterly CEMI's Income Statement


CEMI Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December -7.65 % 70.56 % -0.39 % -29.53 %
3rd Quarter September 22.27 % 86.69 % 100.98 % 1.36 %
2nd Quarter June -51.33 % -25.92 % -25.51 % 15.54 %
1st Quarter March -8.51 % -14.76 % 0.15 % 9.35 %
FY (Year on Year)   3.58 % 47.24 % -5.77 % -


Back to CEMI Growth rate Comparisons >> Back to CEMI Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #252
Healthcare Sector #664
Overall #4457

Revenue Y/Y Growth Statistics
High Average Low
115.68 % 14.13 % -99.9 %
(Mar 31 2022)   (Jun 30 2016)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #252
Healthcare Sector #664
Overall #4457
Revenue Y/Y Growth Statistics
High Average Low
115.68 % 14.13 % -99.9 %
(Mar 31 2022)   (Jun 30 2016)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Chembio Diagnostics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
100.98 % 6.83 % -51.31 %
(Sep 30 2020)  


CEMI's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Chembio Diagnostics Inc disclosed drop in Revenue from the third quarter by -7.65% to $ 10.34 millions, from $ 11.20 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 215 other companies have achieved higher Revenue quarter on quarter growth. While Chembio Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 3183.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #216
Healthcare Sector #540
Overall #3183
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #216
Healthcare Sector #540
Overall #3183
Revenue Q/Q Growth Statistics
High Average Low
100.98 % 6.83 % -51.31 %
(Sep 30 2020)  


CEMI's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Chembio Diagnostics Inc disclosed drop in Revenue from the third quarter by -7.65% to $ 10.34 millions, from $ 11.20 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 215 other companies have achieved higher Revenue quarter on quarter growth. While Chembio Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 3183.


Chembio Diagnostics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 49.52 $ 59.75 $ 60.61 $ 57.91 $ 47.82
Y / Y Revenue Growth (TTM) 3.56 % 59.46 % 69.84 % 68.66 % 47.27 %
Year on Year Revenue Growth Overall Ranking # 630 # 243 # 362 # 287 # 361
Seqeuential Revenue Change (TTM) -17.12 % -1.42 % 4.66 % 21.11 % 27.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 1047 # 1509 # 1075 # 293 # 171


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Chembio Diagnostics Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of 27.61% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Chembio Diagnostics Inc 's Revenue growth from the 11.2% growth in Sep 30 2022.

In the Healthcare sector 120 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 243 to 630.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 85
Healthcare Sector # 121
Overall # 630

Revenue TTM Y/Y Growth Statistics
High Average Low
69.84 %
 12.08 %
-33.03 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 85
Sector # 173
S&P 500 # 1047
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Chembio Diagnostics Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of -33.03% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Chembio Diagnostics Inc 's Revenue growth from the 11.2% growth in Sep 30 2022.

In the Healthcare sector 120 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 243 to 630.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 85
Healthcare Sector # 121
Overall # 630

Revenue TTM Y/Y Growth Statistics
High Average Low
69.84 %
12.08 %
-33.03 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 85
Sector # 173
S&P 500 # 1047




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CEMI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Chembio Diagnostics Inc Revenue Growth Rates (CEMI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Chembio Diagnostics Inc (CIK 1092662).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001140361-23-014526
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Chembio Diagnostics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.